Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
cRGD-ZW800-1 for Fluorescence Imaging in Oral Cancer Surgery
NCT04191460Phase 2Completed
- Sponsor
- Erasmus MC
- Start
- Jul 2022
- Primary completion
- May 2025
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label trial of cRGD-ZW800-1 in oral cancer (3 arms), sponsored by Erasmus MC. Primary endpoints: Mean tumor-to-background ratio and Rate of adequate tumor resection margins. Started Jul 2022; status: completed.
02
Drugs
cRGD-ZW800-1
03
Conditions
oral cancer
Beyond the preview
Go deeper on NCT04191460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04191460.